Close Menu

lawsuit

The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.

Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."

The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.

In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.

Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.

The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."

As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.

A federal judge upheld a $24 million jury award to Bio-Rad, while a trade court judge said Bio-Rad imported microfluidics that infringed 10x patents.

Guardant told a federal judge that it believes Foundation Medicine and Personal Genome Diagnostics are coordinating to invalidate its patents.

The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.

Pages

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.